novel developments in relapsed/refractory hl: checkpoint inhibitors, bispecifics and car-t cells
Published 1 year ago • 53 plays • Length 3:51Download video MP4
Download video MP3
Similar videos
-
0:58
novel approaches in richter's transformation: car-t and bispecifics
-
4:58
novel immunotherapies transforming r/r myeloma treatment: bispecifics, car-t cells & more
-
4:17
novel car t-cell therapies for hematological malignancies: exploring new targets
-
0:49
novel targets for car-t therapy in mcl
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:06
how will novel agents & car-t cells affect the future treatment landscape in b-all?
-
2:48
the novel icaht grading system to predict toxicity following car t-cell therapy
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
1:06
novel third-generation tlr2 co-stimulatory car-t cells for b-cell malignancies
-
1:14
novel inducers of apoptosis in double-refractory cll cells
-
1:34
cctx-001: a novel car-t therapy for aml
-
1:50
the value of moving novel agents into the frontline setting in all
-
1:14
pd-l1 inhibitors in r/r hodgkin lymphoma
-
4:34
development and evaluation of a novel car-t cell therapy against calr mutant neoplasms
-
1:59
updates on the use of nivolumab in hodgkin lymphoma & how this agent may impact treatment
-
1:21
novel approaches to harnessing the immune system in lymphoma
-
2:39
new findings and challenges in the use of immunotherapy in hodgkin lymphoma
-
1:40
checkpoint inhibitors in hodgkin lymphoma